Clinical Trial Update: Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating tislelizumab-based conversion therapy followed by surgery and radiotherapy for N3-stage III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Liaoning Cancer Hospital & Institute | Conditions: Non-Small Cell Lung Cancer (Stage III) | Phase 2 | Status: NOT_YET_RECRUITING